Febrile Neutropenia References

REFERENCES

Brown CH. Febrile neutropenia infections. US Pharm. 2013;38(5)(Suppl Oncology Suppl):3-7. http://www.uspharmacist.com/content/s/249/c/40719/. Accessed 05 Sep 2013
De Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010 May;21(Suppl 5):v252-v256. doi: 10.1093/annonc/mdq196. PMID: 20555092
D’Antonio D, di Girolamo A, Iacone A, et al. Evaluation of azlocillin-amikacin combination for empirical therapy of infection in febrile neutropenic patients. J Chemother. 1989 Dec;1(6):407-412. PMID: 2693624
DePauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med. 1994 May;120(10):834-844. PMID: 8154643
Fishman A, Chowers M, Altaras M, et al. Aztreonam plus piperacillin-empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplastin-based chemotherapy. Eur J Gynaecol Oncol. 1998;19(2):126-129. PMID: 9611050
Freifeld A, Marchigiani D, Walsh T, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999 Jul;341(5):305-311. PMID: 10423464
Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb;52(4):e56-e93. http://www.ncbi.nlm.nih.gov/pubmed/21258094. PMID: 21258094
Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar;34(6):730-751. PMID: 11850858
Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsien for the Infectious Diseases Research and Education, CY Lee’s Research Foundation for Pediatric. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005 Dec;38(6):455-457. PMID: 16341349
Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemein. Ann Hematol. 2003 Oct;82(Suppl 2):S105-S117. PMID: 13680173
Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999 Jul;341(5):312-318. PMID: 10423465
Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents. 2005 Dec;26(Suppl 2):S128-S132. PMID: 16253480
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep;351(14):1391-1402. PMID: 15459300
Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients: a randomized, double-blind trial. Ann Intern Med. 2002 Jul;137(2):77-86. PMID: 12118962
Mortimer J, Miller S, Black D, et al. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med. 1998 Jul;85:17-20. PMID: 3400679
MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
NCCN Fever and Neutropenia Panel Members. Fever and neutropenia. Version 1.2004. NCCN practice guidelines in oncology - v.1.2004. http://www.nccn.org/. 2004.
Ahmed NM. Management of fever in children with non- chemotherapy-induced neutropenia. UpToDate. https://www.uptodate.com/. Sep 2010. Accessed 14 Feb 2011.
Robbins GK. Fever in the neutropenic adult patient with cancer. UpToDate. https://www.uptodate.com/. Sep 2010. Accessed 14 Feb 2011.
Bertuch AA. Fever in children with chemotherapy-induced neutropenia. UpToDate. https://www.uptodate.com. Sep 2010. Accessed 14 Feb 2011.
National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. NCCN Practice guidelines in oncology - v.2.2009. http://www.oralcancerfoundation.org/. Accessed 16 Feb 2011.
National Comprehensive Cancer Network Myeloid Growth Factors Panel Members. Myeloid growth factors. NCCN Practice guidelines in oncology - v.1.2010. http://jhasioncolog.com/. 2010. Accessed 16 Feb 2011.
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: European Society for Medical Oncology (ESMO) clinical practice guidelines. Ann Oncol. 2016 Sep;27(Suppl 5):v111-v118. doi: 10.1093/annonc/mdw325. PMID: 27664247
Averbuch D, Orasch C, Cordonnier C, et al; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013 Dec;98(12):1826-1835. doi: 10.3324/haematol.2013.091025. PMID: 24323983
Bow E. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications. UpToDate. https://www.uptodate.com/. Jan 2020. Accessed 19 Feb 2020.
Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, et al. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol. 2019 Jan;21(1):75-86. doi: 10.1007/s12094-018-1983-4. PMID: 30470991
National Comprehensive Cancer Network. Hematopoietic growth factors. Version 2.2020. NCCN. https://www.nccn.org/. Jan 2020. Accessed 26 Jul 2019.
National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. Version 1.2020. NCCN. https://www.nccn.org/. Dec 2019. Accessed 26 Jul 2019.
Smith TJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015 Oct;33(28):3199-3212. doi: 10.1200/JCO.2015.62.3488. PMID: 26169616
Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update. J Clin Oncol. 2018 Oct;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Accessed 26 Jul 2019. PMID: 30179565
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update. J Clin Oncol. 2018 May;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. PMID: 29461916
Wingard JR. Diagnostic approach to the adult cancer patient with neutropenic fever. UpToDate. https://www.uptodate.com/. Jan 2020. Accessed 19 Feb 2020.
Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). UpToDate. https://www.uptodate.com/. Jan 2020. Accessed 19 Feb 2020.
Wingard JR. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. UpToDate. https://www.uptodate.com/. Jan 2020.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infections. Version 2.2020. NCCN. https://www.nccn.org/. Jun 2020.
Melgar M, Reljic T, Barahona G, et al. Guidance statement for the management of febrile neutropenia in pediatric patients receiving cancer-directed therapy in Central America and the Caribbean. JCO Glob Oncol. 2020 Mar;6:508-517. doi: 10.1200/JGO.19.00329. PMID: 32216650
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hematopoietic growth factors. Version 1.2021. NCCN. https://www.nccn.org/. Feb 2021.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hematopoietic growth factors. Version 4.2021. NCCN. https://www.nccn.org/. May 2021.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hematopoietic growth factors. Version 1.2022. NCCN. https://www.nccn.org/. Dec 2021.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Management of immunotherapy-related toxicities. Version 1.2022. NCCN. https://www.nccn.org/. Feb 2022.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infections. Version 1.2021. NCCN. https://www.nccn.org/. Jul 2021.
Punnapuzha S, Edemobi PK, Elmoheen A. Febrile neutropenia. Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jun.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hematopoietic growth factors. Version 1.2023. NCCN. https://www.nccn.org/. Dec 2022.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infections. Version 3.2022. NCCN. https://www.nccn.org/. Oct 2022.

The role of oral antivirals in COVID-19 treatment: Who, when, and how?

Dr. Roger Paredes, Dr. Nicola Petrosillo, Dr. Petrick Periyasamy, 30 Jan 2023

Though most countries have eased pandemic restrictions, there is no room for complacency in managing COVID-19, which continues to cause significant morbidity and mortality.

At a recent symposium, esteemed experts Dr Roger Paredes, Head of Department of Infectious Diseases at the Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, and Dr Nicola Petrosillo, Head of the Infection Prevention and Control and Infectious Disease Service at University Hospital Campus Bio-Medico, Rome, Italy, gave global perspectives on the continuing unmet needs in the COVID-19 outpatient landscape and discussed the role of antiviral treatment options in patients at risk of progressing to severe COVID-19. Dr Petrick Periyasamy, Head of Infectious Diseases Unit, Medical Department, UKM Medical Centre, Kuala Lumpur, Malaysia, chaired the session.

Product Highlight - XOFLUZA

16 Sep 2020

XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab

Tackling multidrug-resistant gram-negative bacterial infections in critically ill patients: Challenging the standard approach

Dr. Asok Kurup, Dr. Kenneth Chan, 07 Dec 2020

The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam.